Jump to content

Xi says China ready to boost global COVID-19 vaccine cooperation


perugu_vada

Recommended Posts

  • 1 month later...

Brazil researchers now say China’s Sinovac vaccine is 50% effective — lower than announced earlier

The Covid-19 vaccine developed by China’s Sinovac Biotech is just 50.4% effective in a Brazilian trial — barely meeting the threshold for regulatory approval and well below the initially reported efficacy rate, according to several media reports.  

Brazil is the first to complete late-stage trial of the vaccine CoronaVac. The state-run Butantan Institute has been criticized by scientists and health experts for a lack of transparency in making public its trial data.

 

The institute reportedly delayed releasing trial results three times — which it blamed on a confidentially clause in its contract with Sinovac — and last week announced partial data that showed an efficacy rate that was later revised much lower.

Butantan said last week that CoronaVac was 78% effective among volunteers with mild to severe infections, reported the Wall Street Journal. But the institute said Tuesday that the overall efficacy rate fell to 50.4% when including “very mild” cases that did not require medical assistance, the Journal reported.   

In comparison, Covid vaccines from Pfizer-BioNTech and Moderna were found to be about 95% effective in their late-stage trials.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...